Basilea Pharmaceutica AG Allschwil

Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally. This medication is approved for treating invasive aspergillosis and mucormycosis in both the United States and the European Union. Additionally, Cresemba is undergoing Phase III clinical trials in Japan for addressing invasive fungal infections. Another key product is Zevtera, an antibiotic prescribed for both community-acquired and hospital-acquired pneumonia. This antibiotic is also advancing through Phase III clinical studies, investigating its effectiveness against acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. In its development pipeline, Basilea is advancing Derazantinib, a small molecule inhibitor. This compound is currently in Phase 2 clinical trials for bile duct cancer and in Phase 1/2 trials for bladder and stomach cancers. The company is also developing Lisavanbulin, which acts as a tumor checkpoint controller drug. Founded in the year 2000, Basilea Pharmaceutica AG is based in Basel, Switzerland.